Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
COP$138.65+1.71(+1.25%)BRIEF-Conocophillips Q3 Adjusted EPS USD 3.27 Vs. IBES Estimate USD 2.977:13:20 AM ETMU$764.75-30.71(-3.86%)Micron Just Closed Below $800 for the First Time Since July7:12:48 AM ETCRWD$234.50-6.50(-2.70%)Too Late to Buy CrowdStrike Stock? Here's the 1 Thing to Watch.7:10:00 AM ETGOOG$291.60+4.30(+1.50%)These 6 Stocks Make Up a Big Share of the S&P 5007:09:00 AM ETCOP$138.65+1.71(+1.25%)UPDATE 1-ConocoPhillips beats profit estimates, boosts quarterly dividend7:07:07 AM ETLLY$1,435.53+17.39(+1.23%)Iconic California Brand, French Florist, Celebrates Grand Opening of First Indiana Location7:07:00 AM ETCVS$81.17+1.18(+1.48%)ProjectLeo, the First Private AI Health Platform to Declare Independence From Big Tech7:04:00 AM ETCOP$138.65+1.71(+1.25%)ConocoPhillips beats quarterly profit estimates7:01:40 AM ETCOP$138.65+1.71(+1.25%)ConocoPhillips announces third-quarter 2026 results and increases quarterly ordinary dividend by 11%7:00:05 AM ETPG$168.66+1.34(+0.80%)P&G to Webcast Presentation From P&G Investor Day 2026, November 197:00:03 AM ETV$440.80+4.21(+0.96%)Visa Forecasts U.S. Holiday Spending to Rise 4.5% as Consumers Keep the Holidays a Priority7:00:00 AM ETHD$360.09+4.65(+1.31%)Transom Appoints David Shields as Executive Vice President, Operations and Finance7:00:00 AM ETGS$942.00+13.72(+1.48%)RPT-BREAKINGVIEWS-Hong Kong summit exposes Wall Street AI confusion7:00:00 AM ETDTE$138.25+3.99(+2.97%)DTE Energy to sell DTE Vantage business for about $3 billion6:59:28 AM ETACN$268.00+3.73(+1.41%)Mondelēz International and Accenture Transform Order-to-Cash With AI6:59:02 AM ETDNUT$3.63+0.12(+3.42%)Krispy Kreme Q3 revenue falls 12% but beats estimates6:56:38 AM ETC$127.15+2.38(+1.91%)UPDATE 5-Oil rises as investors weigh uncertainties around Iran war6:55:19 AM ETSPCX$133.25-2.67(-1.96%)SpaceX Stock Today Has These 2 Positives. The Stock Is Still Falling.6:48:00 AM ETLLY$1,435.53+17.39(+1.23%)Lilly to showcase new retatrutide, Taltz (ixekizumab) and Zepbound (tirzepatide) data at ACR Convergence 2026, advancing science at the intersection of rheumatologic conditions and obesity6:45:08 AM ETNVDA$197.83-2.46(-1.23%)Nvidia Investors Need to Be Paying Attention on Nov. 176:45:00 AM ETAAPL$352.85+3.34(+0.96%)AI predicts Apple stock price for November 30, 20266:38:48 AM ETJNJ$278.93+2.55(+0.92%)Oxford Brain Diagnostics Wins 2026 CNS Summit Innovation Showcase6:34:27 AM ETTEVA$41.68-0.12(-0.29%)Active Pharmaceutical Ingredients Market Outlook 2032: Valuation to Reach USD 368.7 Billion as Pharmaceutical Manufacturing Demand Expands, Reports Mordor Intelligence6:30:00 AM ETLIN$527.51+2.77(+0.53%)HSBC Continental Europe: Pre Stabilisation Notice6:29:28 AM ET

XERS · NASDAQ

Xeris Biopharma Holdings, Inc.

$11.40 +0.92 (+8.78%)

Company overview

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, develops and commercializes therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$2.1B
Employees
394
Headquarters
Chicago, IL
Website
xerispharma.com
CEO
John Shannon
Listed
June 21, 2018
P/E
162.15
Dividend yield
0.00%

Company financials

Revenue
$315M
Gross profit
$257M
Operating income
$35.9M
EBITDA
$44.9M
Net income
$12M
EPS
$0.07
Total assets
$392M
Total debt
$37.3M
Gross margin
81.59%
Net margin
3.81%
Earnings yield
0.62%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

No geographic segmentation.

Showing FY 2025

Price chart

5.597.108.6110.1311.64
XERS 1D NASDAQ O10.52H10.71L10.15C10.48+0.13 (+1.21%)Vol2.68M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
XERSXeris Biopharma Holdings, Inc. Stock news BRIEF-Xeris Biopharma Q3 Net Income USD 11.29 Million Reuters
XERSXeris Biopharma Holdings, Inc. Press release Xeris Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights Business Wire
XERSXeris Biopharma Holdings, Inc. Press release Xeris Biopharma Welcomes Menassie M. Taddese to Board of Directors Business Wire
XERSXeris Biopharma Holdings, Inc. Stock news Xeris Biopharma Holdings Inc (XERS) Stock Down 6.1% but Still Overvalued -- GF Score: 66/100 GuruFocus
XERSXeris Biopharma Holdings, Inc. Press release Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026 Business Wire
XERSXeris Biopharma Holdings, Inc. Stock news Organon & Co. (NYSE:OGN) & Xeris Biopharma (NASDAQ:XERS) Critical Comparison Defense World
XERSXeris Biopharma Holdings, Inc. Press release Xeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific Meetings Business Wire
XERSXeris Biopharma Holdings, Inc. Stock news Analyzing Xeris Biopharma (NASDAQ:XERS) and Corcept Therapeutics (NASDAQ:CORT) Defense World
XERSXeris Biopharma Holdings, Inc. Press release Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
XERSXeris Biopharma Holdings, Inc. Stock news Lundbeck expresses interest in buying Xeris, Bloomberg News reports Reuters
TLSI Stock news TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday Benzinga
XERSXeris Biopharma Holdings, Inc. Stock news Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Average Recommendation of “Hold” by Analysts Defense World
XERSXeris Biopharma Holdings, Inc. Stock news Xeris Biopharma Holdings, Inc. (XERS) Discusses XP-8121 Program Overview, Phase 3 Study Details and Commercial Strategy Transcript Seeking Alpha
XERSXeris Biopharma Holdings, Inc. Press release Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism Business Wire
XERSXeris Biopharma Holdings, Inc. Press release Xeris Announces Details for XP-8121 Program Overview Webinar Business Wire
XERSXeris Biopharma Holdings, Inc. Stock news Xeris Biopharma: A Commercial Stage Pharma That May Be A Slow-Burn Buy Opportunity Seeking Alpha
XERSXeris Biopharma Holdings, Inc. Stock news Xeris Biopharma Q2 Earnings Call Highlights MarketBeat
XERSXeris Biopharma Holdings, Inc. Stock news Xeris Biopharma Holdings, Inc. (XERS) Q2 2026 Earnings Call Transcript Seeking Alpha
XERSXeris Biopharma Holdings, Inc. Stock news Compared to Estimates, Xeris Biopharma (XERS) Q2 Earnings: A Look at Key Metrics Zacks Investment Research
XERSXeris Biopharma Holdings, Inc. Press release Xeris Biopharma Reports Second Quarter 2026 Financial Results Business Wire
See more
FAQ

Questions about Xeris Biopharma Holdings, Inc.

What does Xeris Biopharma Holdings, Inc. do?
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, develops and commercializes therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
What is XERS's market cap?
Xeris Biopharma Holdings, Inc. (XERS) is a listed stock with a live quote. The latest market cap on this page is $2.1B.
Where is Xeris Biopharma Holdings, Inc. headquartered?
Xeris Biopharma Holdings, Inc. is headquartered in Chicago, IL.
How do I get XERS news from the API?
Call GET /v1/news?tickers=XERS. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does XERS news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for XERS, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the XERS price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs